Major Depressive Disorder

Recommendations that can help clinicians navigate through the reimbursement process and best support patients who receive intranasal esketamine for treatment-resistant depression.

Additional variables that require consideration if treating appropriate patients with treatment-resistant depression with intranasal esketamine within certified treatment facilities.

Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.

Best practices that can be applied when working with patients and training staff on proper ways to administer intranasal esketamine therapy for treatment-resistant depression in a supervised medical setting.

The purpose and impact of the REMS program established to support the integration of intranasal esketamine into clinics that manage treatment-resistant depression.

Practical experience regarding the timing and response to intranasal esketamine therapy for treatment-resistant depression.

Dr. Todd Hutton gives tips for how to best handle the ongoing mental health crisis.

A recent JAMA study shows a decrease in suicide deaths between 2019-2020, despite a 17% overall increase in mortality.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.

New data show mental health workers experienced lower levels of traumatic stress and peritraumatic distress during COVID-19 pandemic, compared to healthcare workers and general population.

New data show significant therapeutic effects of dextraomethadone treatment in MDD patients below the median percentage of life-years from diagnosis.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

Dr. Jennifer Payne discusses how the events of the last year has impacted her patients and what needs to happen to improve mental health care in the future.

The odds of suicidal behavior was 49% lower for OUD patients receiving substance use disorder treatment.

Larger and longer clinical trials are needed to further test the treatment as a suitable option to treat depression.

A recent study finds no substantial increase in risk of suicide in the first months of COVID-19, particularly in high-income countries.

The study represents the first to examine a PPD connection to allopregnanolone.

Contrast suppression was substantially lower for patients with major depressive disorder.

Adults between 18-29 see the largest increase in mental health issues during the pandemic.

Sessions show promise helping alleviate stress and concern for COVID-19.